[Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
Apomorphine, a dopamine-agonist was applied as s. c. infusions to 7 patients with idiopathic Parkinson's disease. The indications were longlasting akinetic episodes (4 patients) and therapeutically resistant invalidating motoric fluctuations ("on-off") as well as hyperkinesia (3 patients) on anti-Parkinson medication. The effect of apomorphine as an anti-Parkinson therapeutic was verified using clinical scales and a portable activity-monitoring device. The s. c. infusion therapy (20-90 mg/die, or 0.025-0.01 mg/kg/die respectively) was effective in the akinetic patients interrupting akinesia and the inability to swallow. An improvement was also registered in patients with "on-off" and hyperkinesia using longlasting subcutaneous apomorphine infusions. The therapy was continued over a longer period of time with 2 patients as outpatients. The side-effects were nausea and local subcutaneous indurations at sites of infusions.
Albani
C
C
Neurologische Klinik, Universitätsspital Zürich.
Zangger
I
I
Fischer
G
G
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects; D001058:Apomorphine / Q000008:administration & dosage* / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D007279:Injections, Subcutaneous / Q000295:instrumentation; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*
D000978:Antiparkinson Agents; D001058:Apomorphine
Subkutane Apomorphininfusionen in der Behandlung der Parkinsonschen Krankheit.